InvestigationalLate-stage / investigational
Survodutide
Also known as:BI 456906
- Class
- Late-stage / investigational
- Route
- SC injection
- Frequency
- Once weekly in trials
- GLP-1 relevance
- Yes
How it works
Dual glucagon/GLP-1 receptor agonist
Approved & studied uses
Obesity; MASH pipeline
Regulatory status
Investigational
Safety notes
No approved human dosing; trial-only.
Sources
Educational reference only. This page does not provide diagnosis, dosing, titration or treatment recommendations. Peptimize does not recommend or adjust any medication schedule - that is between you and your prescriber.